HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma.

Abstract
Seventeen patients with malignant mesothelioma were treated in a phase II study with carboplatin, a cisplatin analogue without significant nephrotoxicity or neurotoxicity. The drug was given in a dose of 300-400 mg/m2 by i.v. infusion, repeating at 28-day intervals. One patient achieved a complete clinical and radiological remission of 15 months' duration, and a second patient achieved a partial response of 11 months' duration (overall response rate 12%; overall response rate in previously untreated patients 20%). Four other previously untreated patients achieved symptomatic relief. Treatment was well tolerated without severe side-effects. Carboplatin, like most other cytotoxic drugs, is active only in a small minority of patients with mesothelioma, but its ability to achieve occasional good responses and frequent symptomatic relief, combined with low toxicity, may justify a short therapeutic trial in patients whose tumour is symptomatic.
AuthorsE K Mbidde, S J Harland, A H Calvert, I E Smith
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 18 Issue 3 Pg. 284-5 ( 1986) ISSN: 0344-5704 [Print] Germany
PMID3542270 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Organoplatinum Compounds
  • Carboplatin
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Carboplatin
  • Drug Evaluation
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Mesothelioma (drug therapy)
  • Middle Aged
  • Organoplatinum Compounds (administration & dosage, adverse effects, therapeutic use)
  • Peritoneal Neoplasms (drug therapy)
  • Pleural Neoplasms (drug therapy)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: